IQVIA Advances Strategic Collaboration with Kexing Biopharm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Source: Newsfilter
- Global Collaboration Acceleration: IQVIA's strategic partnership with Kexing Biopharm aims to support the global multi-product biosimilar development, integrating IQVIA's end-to-end capabilities to accelerate biosimilar development for international markets, which is expected to significantly enhance Kexing's market competitiveness.
- AI Technology Integration: By incorporating IQVIA's AI-enabled clinical trial capabilities, the collaboration will enhance speed and efficiency throughout the development process, assisting Kexing in optimizing decision-making in key areas such as protocol design, site identification, and study execution, thereby improving overall trial performance.
- Support for International Strategy: Kexing Biopharm's General Manager stated that this collaboration will accelerate its internationalization strategy, with IQVIA's global data resources and clinical expertise helping to mitigate regulatory risks and improve overseas registration efficiency, facilitating Kexing's expansion in global markets.
- Industry Leadership Position: As a leading global provider of clinical research services, IQVIA demonstrates its strong capability in driving innovative medical solutions through its deep expertise in biosimilars and global execution capabilities, further solidifying its leadership position in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IQV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IQV
Wall Street analysts forecast IQV stock price to rise
15 Analyst Rating
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 181.090
Low
215.00
Averages
258.31
High
290.00
Current: 181.090
Low
215.00
Averages
258.31
High
290.00
About IQV
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veeva Systems Vault Platform Continues Strong Growth
- Significant Customer Growth: Veeva Systems' Vault CRM platform now has over 125 customers live, including multiple top-20 biopharma companies globally, indicating increased market confidence in its cloud ecosystem and positioning the company for sustained long-term growth.
- Strengthened Strategic Partnerships: Novo Nordisk selected Vault CRM in January 2026 to enhance commercial execution, while Roche and Merck expanded their partnerships with Veeva to adopt Vault CRM for critical product launch cycles, further solidifying Veeva's position in the industry.
- AI-Driven Transformation: The integration of Vault CRM with Veeva AI is accelerating the industry's shift towards agentic CRM and AI-powered commercial engagement, which not only enhances customer engagement but may also lead to increased market share for the company.
- Robust Financial Performance: Despite VEEV's stock price declining by 28.6% year-to-date, its price-to-book ratio stands at 3.63, below the industry average, and the fiscal 2027 earnings estimate suggests a 9.4% improvement, indicating the company's ongoing appeal in terms of innovation and financial health.
See More
April PPI Report Triggers Decline in Healthcare Stocks
- PPI Acceleration Impact: The April PPI report showed a 6% annual increase, with service-sector prices rising at the fastest pace in four years, creating dual pressures on the healthcare sector, increasing operating costs and potentially impacting profitability.
- Cost Pressure: Monthly service-sector inflation rose by 1.2%, significantly increasing operating costs for hospital systems and providers, which may weaken their profitability and affect future investment decisions.
- Regulatory Intervention Risk: As inflation becomes a political focal point, drug companies, due to their visible pricing power, are primary targets for regulatory intervention, which could suppress industry profits.
- Market Overreaction: Despite healthcare stocks like Repligen and AdaptHealth falling by 3.2% and 3.6% respectively, the market's overreaction may present investors with good opportunities to buy high-quality stocks.
See More
IQVIA Advances Strategic Collaboration with Kexing Biopharm
- Global Collaboration Acceleration: IQVIA's strategic partnership with Kexing Biopharm aims to support the global multi-product biosimilar development, integrating IQVIA's end-to-end capabilities to accelerate biosimilar development for international markets, which is expected to significantly enhance Kexing's market competitiveness.
- AI Technology Integration: By incorporating IQVIA's AI-enabled clinical trial capabilities, the collaboration will enhance speed and efficiency throughout the development process, assisting Kexing in optimizing decision-making in key areas such as protocol design, site identification, and study execution, thereby improving overall trial performance.
- Support for International Strategy: Kexing Biopharm's General Manager stated that this collaboration will accelerate its internationalization strategy, with IQVIA's global data resources and clinical expertise helping to mitigate regulatory risks and improve overseas registration efficiency, facilitating Kexing's expansion in global markets.
- Industry Leadership Position: As a leading global provider of clinical research services, IQVIA demonstrates its strong capability in driving innovative medical solutions through its deep expertise in biosimilars and global execution capabilities, further solidifying its leadership position in the industry.
See More
IQVIA Authorizes $2 Billion Stock Buyback
- Buyback Program Expansion: IQVIA's board has authorized an additional $2 billion stock repurchase, increasing the total remaining authorization to $3.2 billion, reflecting the company's confidence in its stock value and aiming to enhance shareholder returns.
- Flexible Repurchase Strategy: The repurchase program does not obligate IQVIA to buy back a specific amount of stock, allowing management to adjust the timing and amount of repurchases based on market prices and overall market conditions, thereby optimizing capital allocation.
- Market Transaction Methods: IQVIA plans to execute stock repurchases through various methods including open market transactions, block trades, or privately negotiated transactions, which helps effectively implement the buyback program under different market conditions.
- Ongoing Repurchase Commitment: The buyback program has no expiration date, indicating that the company may continue to repurchase shares in the future to respond to market changes and bolster investor confidence, further solidifying its leadership position in the life sciences sector.
See More
IQVIA Q1 Earnings Exceed Expectations
- Strong Earnings Performance: IQVIA reported a Q1 non-GAAP EPS of $2.90, beating expectations by $0.08, which reflects the company's robust profitability and enhances investor confidence in its financial health.
- Significant Revenue Growth: The company achieved total revenue of $4.15 billion, an 8.4% year-over-year increase, surpassing market expectations by $50 million, indicating sustained growth momentum in both commercial solutions and R&D sectors.
- Outstanding R&D Solutions Performance: R&D Solutions revenue reached $2.397 billion, up 6.2% year-over-year, with a contracted backlog of $34.2 billion, demonstrating strong market demand and sustainability of future revenues.
- Robust Cash Flow: Operating cash flow stood at $618 million, with free cash flow of $491 million, up 15% year-over-year, indicating effective capital management, while the company repurchased $552 million in stock, enhancing shareholder returns.
See More
Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
See More
Veeva Systems Vault Platform Continues Strong Growth
- Significant Customer Growth: Veeva Systems' Vault CRM platform now has over 125 customers live, including multiple top-20 biopharma companies globally, indicating increased market confidence in its cloud ecosystem and positioning the company for sustained long-term growth.
- Strengthened Strategic Partnerships: Novo Nordisk selected Vault CRM in January 2026 to enhance commercial execution, while Roche and Merck expanded their partnerships with Veeva to adopt Vault CRM for critical product launch cycles, further solidifying Veeva's position in the industry.
- AI-Driven Transformation: The integration of Vault CRM with Veeva AI is accelerating the industry's shift towards agentic CRM and AI-powered commercial engagement, which not only enhances customer engagement but may also lead to increased market share for the company.
- Robust Financial Performance: Despite VEEV's stock price declining by 28.6% year-to-date, its price-to-book ratio stands at 3.63, below the industry average, and the fiscal 2027 earnings estimate suggests a 9.4% improvement, indicating the company's ongoing appeal in terms of innovation and financial health.
See More
April PPI Report Triggers Decline in Healthcare Stocks
- PPI Acceleration Impact: The April PPI report showed a 6% annual increase, with service-sector prices rising at the fastest pace in four years, creating dual pressures on the healthcare sector, increasing operating costs and potentially impacting profitability.
- Cost Pressure: Monthly service-sector inflation rose by 1.2%, significantly increasing operating costs for hospital systems and providers, which may weaken their profitability and affect future investment decisions.
- Regulatory Intervention Risk: As inflation becomes a political focal point, drug companies, due to their visible pricing power, are primary targets for regulatory intervention, which could suppress industry profits.
- Market Overreaction: Despite healthcare stocks like Repligen and AdaptHealth falling by 3.2% and 3.6% respectively, the market's overreaction may present investors with good opportunities to buy high-quality stocks.
See More
IQVIA Advances Strategic Collaboration with Kexing Biopharm
- Global Collaboration Acceleration: IQVIA's strategic partnership with Kexing Biopharm aims to support the global multi-product biosimilar development, integrating IQVIA's end-to-end capabilities to accelerate biosimilar development for international markets, which is expected to significantly enhance Kexing's market competitiveness.
- AI Technology Integration: By incorporating IQVIA's AI-enabled clinical trial capabilities, the collaboration will enhance speed and efficiency throughout the development process, assisting Kexing in optimizing decision-making in key areas such as protocol design, site identification, and study execution, thereby improving overall trial performance.
- Support for International Strategy: Kexing Biopharm's General Manager stated that this collaboration will accelerate its internationalization strategy, with IQVIA's global data resources and clinical expertise helping to mitigate regulatory risks and improve overseas registration efficiency, facilitating Kexing's expansion in global markets.
- Industry Leadership Position: As a leading global provider of clinical research services, IQVIA demonstrates its strong capability in driving innovative medical solutions through its deep expertise in biosimilars and global execution capabilities, further solidifying its leadership position in the industry.
See More
IQVIA Authorizes $2 Billion Stock Buyback
- Buyback Program Expansion: IQVIA's board has authorized an additional $2 billion stock repurchase, increasing the total remaining authorization to $3.2 billion, reflecting the company's confidence in its stock value and aiming to enhance shareholder returns.
- Flexible Repurchase Strategy: The repurchase program does not obligate IQVIA to buy back a specific amount of stock, allowing management to adjust the timing and amount of repurchases based on market prices and overall market conditions, thereby optimizing capital allocation.
- Market Transaction Methods: IQVIA plans to execute stock repurchases through various methods including open market transactions, block trades, or privately negotiated transactions, which helps effectively implement the buyback program under different market conditions.
- Ongoing Repurchase Commitment: The buyback program has no expiration date, indicating that the company may continue to repurchase shares in the future to respond to market changes and bolster investor confidence, further solidifying its leadership position in the life sciences sector.
See More
IQVIA Q1 Earnings Exceed Expectations
- Strong Earnings Performance: IQVIA reported a Q1 non-GAAP EPS of $2.90, beating expectations by $0.08, which reflects the company's robust profitability and enhances investor confidence in its financial health.
- Significant Revenue Growth: The company achieved total revenue of $4.15 billion, an 8.4% year-over-year increase, surpassing market expectations by $50 million, indicating sustained growth momentum in both commercial solutions and R&D sectors.
- Outstanding R&D Solutions Performance: R&D Solutions revenue reached $2.397 billion, up 6.2% year-over-year, with a contracted backlog of $34.2 billion, demonstrating strong market demand and sustainability of future revenues.
- Robust Cash Flow: Operating cash flow stood at $618 million, with free cash flow of $491 million, up 15% year-over-year, indicating effective capital management, while the company repurchased $552 million in stock, enhancing shareholder returns.
See More
Yeztugo Injection Faces Insurance Hurdles Despite Initial Uptake
- Market Acceptance: Since its June launch, Yeztugo has seen usage climb to nearly 75 patients, significantly lower than the expected 700 PrEP patients, indicating a lack of interest among patients that hampers Gilead's market expansion strategy.
- Insurance Coverage Issues: While Gilead claims over 90% of insurers cover Yeztugo, many patients face injection costs exceeding $14,000 and insurance denials, leading them to opt for cheaper daily medications, which impacts sales growth.
- Prescription Data Comparison: In the first quarter, over 9,000 prescriptions were written for Yeztugo, compared to 461,000 for Descovy, highlighting a preference for traditional daily medications that limits Yeztugo's market share.
- Future Sales Expectations: Analysts estimate that Yeztugo's annual sales could exceed $5 billion by 2032, although current insurance coverage and patient acceptance issues may hinder the achievement of this target.
See More
